Erratum to: Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Erratum to: J Transl Med (2016) 14:241 DOI 10.1186/s12967-016-1002-x

Unfortunately, the original version of this article [1] contained an error. Figures 2 and 7 were the incorrect versions. They have been corrected in the original article and are also included correctly in this erratum.

Fig. 2

Development of LIVP-GFP infection in various tumour cells. Development of LIVP-GFP infection in RLS (green circles), RLS-40 (red circles), KB-3-1 (violet squares), KB-8-5 (black line with open squares) and melanoma B-16 (blue triangles) tumour cells at MOI of 1 (a) and MOI of 10 (b). Cells were incubated with virus for 1 h, washed with PBS and incubated up to the analysis in IMDM supplemented with 2 % FBS. Viral titre was measured by PFU assay. Data of three independent experiments are presented

Fig. 7

Effect of LIVP-GFP treatment on the immune responses of tumour-bearing mice. a Summary data showing a significant increase of the number of IFN-γ-ransecreting splenocytes in LIVP-GFP-treated mice (n = 6) with RLS-40 or with melanoma B-16 tumours. Comparison of immune-related proteins GMC-SF (b) and IL-6 (c) in the blood serum of RLS-40 bearing mice during the treatment with LIVP-GFP (the experimental scheme was shown in Fig. 5a): red circles and blue squares for RLS-40 bearing mice treated with LIVP-GFP and PBS, respectively; black triangles healthy mice receiving PBS. The levels of cytokines in the blood serum were measured by ELISA. For each day, the value of mean ± SEM is shown